The Prostate Cancer Transatlantic Consortium (CaPTC) was formed in 2005 to address the globally disproportionate burden of prostate cancer among Black men. CaPTC is an open consortium comprising a team of prostate cancer scientists, clinicians, survivors, and advocates from North America, Europe, the Caribbean Islands, and West Africa.
CaPTC’s research goals are to:
- explore and quantify the magnitude of prostate cancer morbidity and mortality variance among Black men;
- explore the genetic and environmental etiology of this variance, using valid and reliable instruments and biomarkers; and
- develop ethnically sensitive, targeted approaches that will eliminate globally the prostate cancer disparities of Black men through modifiable risk factors associated with prostate cancer.